Pharvaris N.V.(PHVS)Earnings, Financials & Key Ratios
PHVS•NASDAQ
$30.11
$1.96B mkt cap·Price updated May 6, 2026
AboutPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.Show more
- Revenue$0
- EBITDA-$146M-50.6%
- Net Income-$134M-33.1%
- EPS (Diluted)-2.48+5.7%
- ROE-41.18%-8.9%
- Debt/Equity0.00+417.2%
PHVS Key Insights
Pharvaris N.V. (PHVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 40.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PHVS Price & Volume
Pharvaris N.V. (PHVS) stock price & volume — 10-year historical chart
Loading chart...
PHVS Growth Metrics
Pharvaris N.V. (PHVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-19.18%
Return on Capital
10 Years-54.1%
5 Years-43.14%
3 Years-43.3%
Last Year-44.66%
PHVS Recent Earnings
Pharvaris N.V. (PHVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)
Q2 2026Latest
Apr 2, 2026EPS
$0.85
Est $0.71
-18.3%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.70
Est $0.78
+10.3%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.94
Est $0.87
-8.0%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.89
Est $0.80
-11.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 2, 2026 | $0.85vs $0.71-18.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.70vs $0.78+10.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.94vs $0.87-8.0% | — |
| Q2 2025 | May 13, 2025 | $0.89vs $0.80-11.3% | — |
Based on last 12 quarters of dataView full earnings history →
PHVS Peer Comparison
Pharvaris N.V. (PHVS) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KALV | 1.37B | 26.72 | -7.24 | -13.91% | -282.01% | 0.07 | ||
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 CGEM | 903.06M | 14.99 | -4.03 | -46.19% | 0.01 | |||
 IQV | 29.95B | 176.47 | 22.51 | 5.87% | 8.33% | 22.11% | 2.44 |
Compare PHVS vs Peers
Pharvaris N.V. (PHVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHVS Income Statement
Pharvaris N.V. (PHVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 614 | 8.44K | 0 | 0 | 0 | 0 | 97.02K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -614▲ 0% | -8.44K▼ 1274.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -97.02K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | -1273.05% | 100% | - | - | - | - |
| Operating Expenses | 4.31M | 8.96M | 28.5M | 54.14M | 86.71M | 96.91M | 145.69M | 85.85M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 668.12K | 2.6M | 6.26M | 18.35M | 29.34M | 31.34M | 47.12M | 46.61M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 3.65M | 6.36M | 22.24M | 35.79M | 57.38M | 65.58M | 98.56M | 123.62M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1000K |
| Operating Income | -4.31M▲ 0% | -8.97M▼ 107.8% | -28.51M▼ 218.0% | -54.14M▼ 89.9% | -86.71M▼ 60.2% | -96.91M▼ 11.8% | -145.69M▼ 50.3% | -85.95M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -107.85% | -217.96% | -89.91% | -60.17% | -11.76% | -50.33% | - |
| EBITDA | 0 | -8.96M | -28.5M | -54.06M | -86.56M | -96.66M | -145.59M | -85.54M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -217.89% | -89.7% | -60.12% | -11.66% | -50.63% | 33.99% |
| D&A (Non-Cash Add-back) | 4.31M | 614 | 8.44K | 77.37K | 152.94K | 257.55K | 95K | 410.51K |
| EBIT | -4.31M | -8.98M | -29.72M | -54.14M | -86.71M | -96.91M | -145.69M | -155.61M |
| Net Interest Income | 0 | 4 | -92.38K | -277.91K | -16.09K | 0 | 5.47M | 5.64M |
| Interest Income | 0 | 4 | 92 | 268 | 16 | 0 | 5.47M | 5.64M |
| Interest Expense | 0 | 0 | 92.47K | 278.18K | 16.11K | 0 | 0 | 0 |
| Other Income/Expense | -380 | -18.89K | -1.21M | 11.48M | 11.06M | -2.91M | 13.29M | -78.44M |
| Pretax Income | -4.31M▲ 0% | -8.98M▼ 108.3% | -29.72M▼ 230.8% | -42.66M▼ 43.6% | -75.65M▼ 77.3% | -99.83M▼ 32.0% | -132.4M▼ 32.6% | -164.39M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 380 | 0 | -94.9K | 70.12K | 679.09K | 1.05M | 1.83M | 1.65M |
| Effective Tax Rate % | -0.01% | 0% | 0.32% | -0.16% | -0.9% | -1.05% | -1.38% | -1% |
| Net Income | -4.31M▲ 0% | -8.98M▼ 108.2% | -29.62M▼ 229.7% | -42.73M▼ 44.2% | -76.33M▼ 78.6% | -100.88M▼ 32.2% | -134.22M▼ 33.1% | -166.04M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -108.25% | -229.72% | -44.25% | -78.64% | -32.15% | -33.06% | -23.29% |
| Net Income (Continuing) | -4.31M | -8.98M | -29.62M | -42.73M | -76.33M | -100.88M | -134.22M | -166.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.14▲ 0% | -0.25▼ 78.6% | -0.85▼ 240.0% | -1.41▼ 65.9% | -2.27▼ 61.0% | -2.63▼ 15.9% | -2.48▲ 5.7% | -2.67▲ 0% |
| EPS Growth % | - | -78.57% | -240% | -65.88% | -60.99% | -15.86% | 5.7% | -19.18% |
| EPS (Basic) | -0.14 | -0.25 | -0.85 | -1.41 | -2.27 | -2.63 | -2.48 | - |
| Diluted Shares Outstanding | 31.84M | 31.84M | 30.52M | 30.41M | 33.59M | 38.39M | 54.02M | 62.26M |
| Basic Shares Outstanding | 31.84M | 31.84M | 30.52M | 30.41M | 33.59M | 38.39M | 54.02M | 62.26M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PHVS Balance Sheet
Pharvaris N.V. (PHVS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.43M | 20.58M | 100.95M | 211.57M | 166.85M | 397.85M | 289.42M | 337.19M |
| Cash & Short-Term Investments | 5.39M | 20.33M | 98.63M | 209.35M | 161.84M | 391.23M | 280.73M | 329.29M |
| Cash Only | 5.39M | 20.33M | 98.63M | 209.35M | 161.84M | 391.23M | 280.73M | 329.29M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 210.84K | 569.58K | 700.08K | 382.47K | 1.04M | 2.94M | 2.94M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 4.04M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 1.21M | 5.7K | 582.59K | 620.82K | 0 | 0 |
| Total Non-Current Assets | 0 | 12.93K | 147.84K | 523.4K | 886.24K | 843.1K | 1.96M | 1.71M |
| Property, Plant & Equipment | 0 | 12.93K | 48.5K | 351.35K | 626.44K | 455.57K | 1.48M | 1.25M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 5.43M▲ 0% | 20.6M▲ 279.0% | 101.1M▲ 390.8% | 212.09M▲ 109.8% | 167.73M▼ 20.9% | 398.69M▲ 137.7% | 291.37M▼ 26.9% | 338.9M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 279.03% | 390.83% | 109.78% | -20.91% | 137.7% | -26.92% | -93.38% |
| Total Current Liabilities | 481.34K | 1.92M | 5.31M | 6.99M | 18.22M | 14.6M | 22.97M | 26.21M |
| Accounts Payable | 246.36K | 517.77K | 656.45K | 2.13M | 5.98M | 2.91M | 4.56M | 2.55M |
| Days Payables Outstanding | - | 307.56K | 28.4K | - | - | - | - | 15.23K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 875.24K | 1.46M | 461.3K | 429.92K | 7.83M | 7.93M |
| Current Ratio | 11.29x | 10.70x | 19.00x | 30.28x | 9.16x | 27.25x | 12.60x | 12.60x |
| Quick Ratio | 11.29x | 10.70x | 19.00x | 30.28x | 8.93x | 27.25x | 12.60x | 12.60x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 246.36K | 0 | 0 | 150.75K | 249.42K | 43.56K | 639.04K | 441.04K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 150.75K | 249.42K | 43.56K | 639.04K | 2.1M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Total Liabilities | 481.34K | 1.92M | 5.31M | 7.14M | 18.47M | 14.65M | 23.61M | 26.66M |
| Total Debt | 0 | 0 | 0 | 250.18K | 436.82K | 238.91K | 861.47K | 578.66K |
| Net Debt | -5.39M | -20.33M | -98.63M | -209.1M | -161.4M | -390.99M | -279.87M | -328.71M |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 3.84x |
| Interest Coverage | - | - | -308.28x | -194.62x | -5384.33x | - | - | - |
| Total Equity | 4.95M▲ 0% | 18.67M▲ 277.0% | 95.79M▲ 412.9% | 204.95M▲ 114.0% | 149.26M▼ 27.2% | 384.05M▲ 157.3% | 267.76M▼ 30.3% | 312.24M▲ 0% |
| Equity Growth % | - | 277.01% | 412.95% | 113.97% | -27.17% | 157.3% | -30.28% | -106.94% |
| Book Value per Share | 0.16 | 0.59 | 3.14 | 6.74 | 4.44 | 10.00 | 4.96 | 5.02 |
| Total Shareholders' Equity | 4.95M | 18.67M | 95.79M | 204.95M | 149.26M | 384.05M | 267.76M | 312.24M |
| Common Stock | 100.93K | 130.96K | 235.69K | 3.98M | 4.06M | 6.27M | 6.53M | 7.8M |
| Retained Earnings | -10.45M | -18.47M | -44.46M | -87.57M | -164.19M | -265.92M | -402.26M | -532.38M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 275.99K | 392.14K | 1.98M | 9.8M | 20.21M | 27.88M | 39.85M | 47.31M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHVS Cash Flow Statement
Pharvaris N.V. (PHVS) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.92M | -6.68M | -21.5M | -44.6M | -67.16M | -93.05M | -120.13M | -120.13M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -70.39% | -221.99% | -107.44% | -50.59% | -38.54% | -29.1% | -106.08% |
| Net Income | -4.31M | -8.03M | -26.07M | -42.66M | -75.65M | -99.83M | -132.4M | -166.04M |
| Depreciation & Amortization | 0 | 549 | 7.4K | 77.37K | 152.94K | 257.55K | 269.56K | 404.44K |
| Stock-Based Compensation | 100.75K | 116.15K | 1.59M | 8.2M | 11.35M | 10.66M | 16.21M | 19.35M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.97K | -3.69K | 1.4M | -11.79M | -11.39M | 1.72M | -10.1M | 1.66M |
| Working Capital Changes | 291.55K | 1.24M | 1.57M | 1.58M | 8.38M | -5.86M | 5.89M | 6.67M |
| Change in Receivables | -49.52K | -208.73K | -358.74K | -130.5K | 317.61K | -41.05K | -34.32K | 245.38K |
| Change in Inventory | 0 | 3.58K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 188.45K | 273.69K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | -13.48K | -42.98K | -130.03K | -124.3K | -89.98K | -538.09K | -324K |
| Capital Expenditures | 0 | -13.48K | -42.98K | -130.03K | -124.3K | -89.98K | -538.09K | -324K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.51M | 21.63M | 101.2M | 143.67M | 8.65M | 325.39M | 2.68M | 160.9M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -119.53K | -220.51K | -159.66K | -179.28K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.62M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -836.18K | -1.31M | -13.15M | -839.97K | -17.3M | 592K | -10.91M |
| Net Change in Cash | 590.2K▲ 0% | 14.94M▲ 2431.5% | 78.3M▲ 424.1% | 110.72M▲ 41.4% | -47.52M▼ 142.9% | 229.39M▲ 582.8% | -110.5M▼ 148.2% | 24.09M▲ 0% |
| Free Cash Flow | -3.92M▲ 0% | -6.69M▼ 70.7% | -21.54M▼ 222.0% | -44.73M▼ 107.6% | -67.29M▼ 50.4% | -93.14M▼ 38.4% | -120.67M▼ 29.6% | -134.4M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -70.73% | -221.99% | -107.63% | -50.43% | -38.42% | -29.56% | -22.86% |
| FCF per Share | -0.12 | -0.21 | -0.71 | -1.47 | -2.00 | -2.43 | -2.23 | -2.23 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.74x | 0.73x | 1.04x | 0.88x | 0.92x | 0.90x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHVS Key Ratios
Pharvaris N.V. (PHVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -76.05% | -51.76% | -28.42% | -43.1% | -37.83% | -41.18% | -53.18% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 481.16% |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | - | -308.28x | -194.62x | -5384.33x | - | - | - |
| FCF Conversion | 0.74x | 0.73x | 1.04x | 0.88x | 0.92x | 0.90x | 0.81x |
PHVS Frequently Asked Questions
Pharvaris N.V. (PHVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pharvaris N.V. (PHVS) grew revenue by 0.0% over the past year. Growth has been modest.
Pharvaris N.V. (PHVS) reported a net loss of $166.0M for fiscal year 2024.
Dividend & Returns
Pharvaris N.V. (PHVS) has a return on equity (ROE) of -41.2%. Negative ROE indicates the company is unprofitable.
Pharvaris N.V. (PHVS) had negative free cash flow of $134.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More PHVS
Pharvaris N.V. (PHVS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates